MX2023002024A - Métodos de tratamiento con modulador de miosina. - Google Patents

Métodos de tratamiento con modulador de miosina.

Info

Publication number
MX2023002024A
MX2023002024A MX2023002024A MX2023002024A MX2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A
Authority
MX
Mexico
Prior art keywords
treatment
methods
disclosed
myosin
modulator
Prior art date
Application number
MX2023002024A
Other languages
English (en)
Inventor
Jay M Edelberg
Amy Sehnert
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2023002024A publication Critical patent/MX2023002024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

En el presente documento se describen métodos de tratamiento que comprenden la administración de una cantidad terapéuticamente eficaz de un modulador de miosina o una sal farmacéuticamente aceptable del mismo a un sujeto que lo necesite, así como métodos de diagnóstico útiles en relación con los tratamientos. También se dan a conocer tratamientos realizados en ausencia de terapia con betabloqueantes o con terapia reducida con betabloqueantes.
MX2023002024A 2020-08-28 2021-08-26 Métodos de tratamiento con modulador de miosina. MX2023002024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072094P 2020-08-28 2020-08-28
PCT/US2021/047711 WO2022047004A1 (en) 2020-08-28 2021-08-26 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
MX2023002024A true MX2023002024A (es) 2023-05-10

Family

ID=80355673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002024A MX2023002024A (es) 2020-08-28 2021-08-26 Métodos de tratamiento con modulador de miosina.

Country Status (9)

Country Link
EP (1) EP4203927A1 (es)
JP (1) JP2023540485A (es)
KR (1) KR20230079053A (es)
CN (1) CN116490185A (es)
AU (1) AU2021334316A1 (es)
CA (1) CA3190060A1 (es)
IL (1) IL300775A (es)
MX (1) MX2023002024A (es)
WO (1) WO2022047004A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38057A (es) 2018-01-19 2019-08-30 Cytokinetics Inc Inhibidores de sarcómero cardíaco
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US11414424B2 (en) 2018-08-31 2022-08-16 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
US20230338378A1 (en) * 2022-04-26 2023-10-26 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
WO2024086821A1 (en) * 2022-10-21 2024-04-25 Prolaio, Inc. System and method of treatment of hypertrophic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200035973A (ko) * 2017-08-04 2020-04-06 미요카디아, 인크. 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐
CN111116492B (zh) * 2019-01-25 2021-07-09 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
MX2022005465A (es) * 2019-11-10 2022-08-08 Myokardia Inc Metodos de tratamiento con modulador de miosina.

Also Published As

Publication number Publication date
WO2022047004A1 (en) 2022-03-03
JP2023540485A (ja) 2023-09-25
CN116490185A (zh) 2023-07-25
CA3190060A1 (en) 2022-03-03
AU2021334316A1 (en) 2023-05-04
EP4203927A1 (en) 2023-07-05
IL300775A (en) 2023-04-01
KR20230079053A (ko) 2023-06-05

Similar Documents

Publication Publication Date Title
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
MX2022005465A (es) Metodos de tratamiento con modulador de miosina.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2023001717A (es) Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2022000143A (es) Metodos novedosos.
Misra et al. Prevention of PONV by acustimulation with capsicum plaster is comparable to ondansetron after middle ear surgery
MX2020011295A (es) Tratamiento de dermatitis atopica.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
AU2021339851A8 (en) Method of treating amyloidosis
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
ZA202201446B (en) Methods of treating multifocal cancer
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
BR112022025920A2 (pt) Tratamento de artrite reumatoide
MX2022010006A (es) Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo.